Erratum: Effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: A randomized, placebo-controlled trial The error specifically relates to our secondary analyses of the metabolic blood markers. In these analyses, the coding of "visit type"
had been shuffled, and in turn, the data and statistical tests of the metabolic blood markers in Section 2.6.4 and Table 1 were based on incorrect visit types. 2 Reductions in body weight are typically associated with improvement in metabolic blood markers, and our unexpected report of a post-intervention worsening of blood metabolic variables after 3 months, was therefore incorrect and misleading.
Below, we present a corrected version of Table 1 , and we also present a modified Results section. Finally, we briefly discuss the implications of these corrected secondary analyses.
| CORRECTED RESULTS
These corrected results correspond to the second paragraph Section 3.2 in the original paper. 2 Changes are shown in italic font.
Plasma exenatide significantly increased in the exenatide group compared to the placebo group (P = .002; Table 1 Regarding plasma exenatide, we found an effect of Group (P < .001), but no effect of Group was found for any other secondary outcomes. Post hoc correction for smoking status did not significantly change results concerning any secondary outcomes.
| IMPLICATIONS
Regardless of treatment arm, the moderate weight loss of 2. 
| COMMENT
The reported error had minor overall impact on our study; however, the premise for progress in research is the availability of accurate data, and our originally reported blood metabolic parameters were misleading. We have meticulously checked all analyses related to this study, and we confidently claim that no other mistakes are present.
Please accept our sincere apologies for this unfortunate inaccuracy.
May this attempt to provide transparency not compromise confidence in the presented data. 
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